Arcus Biosciences, Inc. (RCUS)
29.66
-0.47
(-1.56%)
USD |
NYSE |
Sep 04, 16:00
29.66
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Research and Development Expense (Quarterly) : 113.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 113.00M |
| March 31, 2026 | 122.00M |
| December 31, 2025 | 121.00M |
| September 30, 2025 | 141.00M |
| June 30, 2025 | 139.00M |
| March 31, 2025 | 122.00M |
| December 31, 2024 | 101.00M |
| September 30, 2024 | 123.00M |
| June 30, 2024 | 115.00M |
| March 31, 2024 | 109.00M |
| December 31, 2023 | 93.00M |
| September 30, 2023 | 82.00M |
| June 30, 2023 | 84.00M |
| March 31, 2023 | 81.00M |
| December 31, 2022 | 80.20M |
| September 30, 2022 | 76.68M |
| June 30, 2022 | 69.90M |
| March 31, 2022 | 61.21M |
| Date | Value |
|---|---|
| December 31, 2021 | 49.94M |
| September 30, 2021 | 71.25M |
| June 30, 2021 | 68.77M |
| March 31, 2021 | 66.39M |
| December 31, 2020 | 48.71M |
| September 30, 2020 | 51.80M |
| June 30, 2020 | 35.69M |
| March 31, 2020 | 23.14M |
| December 31, 2019 | 20.69M |
| September 30, 2019 | 17.24M |
| June 30, 2019 | 25.00M |
| March 31, 2019 | 15.55M |
| December 31, 2018 | 11.44M |
| September 30, 2018 | 12.86M |
| June 30, 2018 | 13.70M |
| March 31, 2018 | 11.65M |
| December 31, 2017 | 12.15M |
| September 30, 2017 | 21.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 27.66M |
| AVITA Medical, Inc. | 5.078M |
| Iovance Biotherapeutics, Inc. | 58.85M |
| Editas Medicine, Inc. | 19.76M |
| Recursion Pharmaceuticals, Inc. | 77.91M |